The Role of Resistant Starch in COVID-19 Infection

Phase 2

Terminated

• Conditions: COVID-19
• Interventions: Drug: Dietary Supplement containing resistant starch; Dietary Supplement: Placebo Starch

• Registration Number: NCT04342689
• Lead Sponsor: Yale University

Brief Summary

This study is a multicenter randomized trial to evaluate the efficacy of administering a dietary supplement containing resistant starch to non-hospitalized COVID-19 positive subjects, The intervention will begin as soon as possible after subjects test positive for COVID-19 and continue for 14 days. Investigators hypothesize that short-term administration of a dietary supplement containing resistant starch has the potential to reduce rates of hospitalization and improve time to clinical recovery and symptoms in non-hospitalized COVID-19 positive patients.

Detailed Description

The COVID-19 pandemic has caused a substantial strain on the healthcare system, with at least 14% of infected patients requiring hospitalization. Identifying ways to ameliorate the progression and severity of the COVID-19 infection and preventing hospitalization is critical. Patients suffering from COVID-19 have been shown to have a significant inflammatory response resembling that of cytokine release syndrome, and it is this inflammatory phase that is thought to drive fatality.

To this end, a multi-center randomized clinical trial to determine the efficacy of resistant starch in reducing the need for hospitalization for COVID-19 positive patients will be studied. This study will enroll 1500 non-hospitalized COVID-19 positive individuals who are being monitored in the outpatient setting. Patients will be randomized to either a dietary supplement containing resistant starch or a placebo for 14 days. Our primary outcome is the rate of hospitalization for COVID-19 related complications. Secondary outcomes will look at time to recovery and symptom severity scores.

Study Timeline

• Study First Submitted: 2020-04-08
• Study First Submitted QC: 2020-04-08
• Study First Posted: 2020-04-13
• Study Start: 2020-06-03
• Primary Completion: 2021-04-15
• Study Completion: 2021-04-15
• Results First Submitted: 2022-07-06
• Status Verified: 2022-09
• Results First Submitted QC: 2022-09-27
• Last Update Submitted: 2022-09-27
• Results First Posted: 2022-10-05
• Last Update Posted: 2022-10-05

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 226

Inclusion Criteria

• greater than 18 years of age
• COVID-positive status
• Being monitored in an outpatient setting at one of our study sites:
• Yale New Haven Hospital (YNHH)
• University of Michigan
• University of Minnesota

Read More

Exclusion Criteria

• inflammatory bowel disease
• history of gastric bypass surgery
• active Clostridium difficile infection
• active participation in another COVID-19 interventional trial
• any physical or psychological condition that, in the opinion of the investigator, would pose unacceptable risk to the patient or raise concern that the patient would not comply with the protocol procedures.
• Reported allergy to starch
• Difficulty swallowing in order to prevent any aspiration risk
• Currently taking any IL-6 inhibitors such as Tocilizumab for any disease condition

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention	Dietary Supplement containing resistant starch	Subjects will receive a dietary supplement containing resistant starch and be instructed to take 2 tablespoons (\~20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days prior to increasing to 2 tablespoons twice daily.
Control	Placebo Starch	Subjects will receive a placebo starch, consisting of non resistant starch and be instructed to take 2 tablespoons (\~ 20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days.

Primary Outcome Measures

Name	Time	Method
Count of Participant Hospitalization for a COVID-19 Related Complication (Phase 3)	One month from the start of treatment	Hospitalization for a COVID-19 related admission during the first month of follow up. Death prior to hospitalization thought to be secondary to COVID-19 will also be defined as an event.

Secondary Outcome Measures

Name	Time	Method
Time to Clinical Recovery (TTCR) (Phase 2)	One month from the start of treatment, up to 4 months	Time to clinical recovery will be defined by a return to normal body temperature (97-99 degrees F) as reported by the patient, and resolution of major presenting symptoms (myalgia, cough, shortness of breath, and GI symptoms) maintained for 72 hours. Patients will be called every 2 days for the first 14 days of the study, and then once weekly for the following 14 days to assess symptoms via a pre-specified questionnaire. Patients will be followed from the start of treatment to the end of follow-up at 4 months.
Peak Symptom Severity Score (Phase 2)	One month from the start of treatment, up to 4 months	This score will be evaluated using a subjective self-reporting questionnaire around 8 symptoms, which include: shortness of breath at rest or exertion, fatigue, myalgia/muscle aces, fever, cough, headache, GI symptoms, inability to taste or smell. Subjects will rate each of their symptoms on an ordinal scale as follows: absent (0), mild (1), moderate (2), or severe (3). These symptom ratings will be added to define the symptom severity score with a possible score range of 0-24 points. Subjects will be called every 2 days for the first 14 days of the study, and then once weekly for the following 14 days to assess symptoms via this pre-specified questionnaire. Patients will be followed from the start of treatment to the end of follow-up at 4 months. "Peak" was added to the outcome title (to correctly identify the measure) when results were entered.

Trial Locations

Locations (2)

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States

Yale University; 🇺🇸 New Haven, Connecticut, United States